Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

84.55USD
11:49am EDT
Change (% chg)

$-0.20 (-0.24%)
Prev Close
$84.75
Open
$84.47
Day's High
$84.74
Day's Low
$84.35
Volume
161,867
Avg. Vol
1,396,863
52-wk High
$86.13
52-wk Low
$64.25

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.34
Market Cap(Mil.): $93,509.28
Shares Outstanding(Mil.): 1,103.35
Dividend: 0.52
Yield (%): 2.45

Financials

  LLY.N Industry Sector
P/E (TTM): 32.87 29.37 30.15
EPS (TTM): 2.58 -- --
ROI: 9.94 13.51 13.05
ROE: 19.16 14.42 14.20

BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

* Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent

Mar 28 2017

BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln

* CEO John C. Lechleiter's 2016 total compensation was $18.4 million versus $16.6 million in 2015

Mar 20 2017

Federal Circuit revives Cialis patent claims against Lilly

By Jan Wolfe The U.S. Court of Appeals for the Federal Circuit has breathed new life into a research institute’s claims that Eli Lilly and Co’s erectile dysfunction drug Cialis infringes on one of its patents.

Feb 28 2017

Accera's Alzheimer's trial fails, in yet another setback for disease

Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.

Feb 28 2017

Accera's Alzheimer's trial fails, in yet another setback for disease

Feb 28 Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease.

Feb 28 2017

AARP, Eli Lilly support Sanofi, Regeneron in cholesterol drug fight

Seniors' advocacy group AARP and drugmaker Eli Lilly & Co on Thursday urged a federal appeals court to overturn a court order barring sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent.

Feb 24 2017

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev

Feb 22 2017

BRIEF-Lilly says provisions included in legislation to repeal Affordable Care Act could adversely affect results

* Provisions included in legislation repealing, replacing affordable care act could have material adverse effect on consolidated results, cash flows Source text - (http://bit.ly/2kIQynP) Further company coverage:

Feb 21 2017

BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine

* Eli Lilly - additional results from pivotal ra-beam study published in New England Journal of Medicine

Feb 15 2017

BRIEF-Adocia 2016 revenue down at 22.4 million euros

* 2016 revenue of 22.4 million euros ($23.7 million), compared to 36.9 million euros in 2015

Feb 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates